Brian Godman1,2,3, Amanj Kurdi1,4, Holly McCabe5, Chris F Johnson6, Corrado Barbui7, Sean MacBride-Stewart6, Simon Hurding8, Axel Leporowski5, Marion Bennie1, Alec Morton5. 1. Strathclyde Institute of Pharmacy & Biomedicial Sciences, University of Strathclyde, Glasgow, UK. 2. Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden. 3. Department of Public Health Pharmacy & Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Garankuwa, South Africa. 4. Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq. 5. Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, UK. 6. Prescribing Support Unit, National Health Service Greater Glasgow & Clyde (NHS GGC), Glasgow, UK. 7. WHO Collaborating Centre for Research & Training in Mental Health & Service Evaluation, Department of Neuroscience, Biomedicine & Movement Sciences, Section of Psychiatry, University of Verona, Italy. 8. Therapeutics Branch, Scottish Government, Edinburgh, UK.
Abstract
Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.
Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.
Entities:
Keywords:
SSRIs; Scottish NHS; drug utilization; expenditure; generics; reforms
Authors: Julius C Mwita; Olayinka O Ogunleye; Adesola Olalekan; Aubrey C Kalungia; Amanj Kurdi; Zikria Saleem; Jacqueline Sneddon; Brian Godman Journal: Int J Gen Med Date: 2021-02-18
Authors: Ileana Mardare; Stephen M Campbell; Johanna C Meyer; Israel Abebrese Sefah; Amos Massele; Brian Godman Journal: Front Pharmacol Date: 2022-01-14 Impact factor: 5.810
Authors: Brian Godman; Magdalene Wladysiuk; Stuart McTaggart; Amanj Kurdi; Eleonora Allocati; Mihajlo Jakovljevic; Francis Kalemeera; Iris Hoxha; Anna Nachtnebel; Robert Sauermann; Manfred Hinteregger; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Juraj Slabý; Radka Nejezchlebova; Iva Selke Krulichová; Ott Laius; Gisbert Selke; Irene Langner; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuolienė; Jolanta Gulbinovič; Patricia Vella Bonanno; Jakub Rutkowski; Skule Ingeberg; Øyvind Melien; Ileana Mardare; Jurij Fürst; Sean MacBride-Stewart; Carol Holmes; Caridad Pontes; Corinne Zara; Marta Turu Pedrola; Mikael Hoffmann; Vasileios Kourafalos; Alice Pisana; Rita Banzi; Stephen Campbell; Bjorn Wettermark Journal: Biomed Res Int Date: 2021-10-11 Impact factor: 3.411